LeonaBio, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LeonaBio, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.61M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($96.94M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($117.67M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($95.64M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($54.85M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($19.96M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($5.16M) | Mar 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($102.27M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($100.90M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($125.47M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($104.02M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($64.02M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($20.00M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($5.45M) | Mar 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.50M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $70.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $93.79M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $61.46M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $42.79M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $13.29M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.79M | Mar 25, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.73M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($97.17M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($100.75M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($72.47M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($43.10M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($24.11M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($3.71M) | Mar 25, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $33.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $304.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.14M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.57M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.32M | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $58.78M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $160.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $258.15M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $332.01M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $279.56M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.19M | Mar 25, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.94M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $30.06M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $23.02M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $10.92M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $5.28M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $4.86M | Mar 25, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.79M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $44.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $130.19M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $235.14M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $321.08M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $274.28M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($19.72M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | ($14.89M) | Mar 25, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($511.76M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($406.15M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($309.21M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($191.53M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($95.90M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($41.04M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($21.09M) | Mar 25, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.28M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $48.44M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $90.58M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $95.97M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $110.54M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $60.63M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.06M | Mar 25, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (24) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (25) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (24) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (25) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.34M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 3.90M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 38.17M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 37.88M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 37.38M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 32.49M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 3.64M | Mar 25, 2021 |